Nycomed AmershamAnnual report and accounts 2000
Our Results

Financial highlights
Throughout this report results are stated before exceptional items and goodwill amortisation. Trading profit represents operating profit before exceptional items and goodwill amortisation and before R&D. Growth rates are at constant exchange unless otherwise indicated.
 
12 months
to 31 Dec 2000
£m
12 months
to 31 Dec 1999
£m
Growth at
constant
exchange rate
%
Continuing business
Sales
1,377.3
1,271.6
10#
-Nycomed Amersham Imaging
773.9
728.8
9#
-Amersham Pharmacia Biotech
603.4
542.7
12#
Trading profit
389.9
377.0
5
Research and development
149.0
126.4
17
Operating profit
240.9
250.6
(2)
Group
Profit before tax
230.9
233.8
-*
Earnings per share
22.5p
21.1p
8*
Dividend per share
6.40p
5.85p
9

# Comparable growth excluding disposed business.
* Continuing business growth adjusted for the impact of the disposal of Pharma.

 

Contents
Chairman's statement

Chief Executive's business review
Nycomed Amersham Imaging Amersham Pharmacia Biotech

Financial review

Community and the environment

Boare of Directors

Report of the Directors

Corporate Governance statement

Glossary

Download Annual report and accounts 2000 as a PDF document [0.4Mb]
back to Investors section

 

© Amersham plc - All rights reserved  Privacy policy - Terms & conditions - GE Healthcare